GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease
Angus T Stock, Jacinta A Hansen, Matthew A Sleeman, Brent S McKenzie, Ian P Wicks
Journal of Experimental Medicine | ROCKEFELLER UNIV PRESS | Published : 2016
Awarded by Australian National Health and Medical Research Council
Awarded by National Heart Foundation of Australia
This work was supported by the Australian National Health and Medical Research Council (program grant 1023407 and Clinical Practitioner Fellowship 0123462 to I.P. Wicks), the National Heart Foundation of Australia (grant 1009427 to I.P. Wicks), and the John T. Reid Charitable Trusts.B.S. McKenzie was employed by CSL Limited and is currently employed by Genentech. I.P. Wick's laboratory has received funding from CSL Limited and MedImmune for research on cytokine antagonists. M.A. Sleeman is an employee of MedImmune, a wholly owned subsidiary of AstraZeneca. MedImmune and AstraZeneca have an anti-human GM-CSFR. chain antibody, mavrilimumab, in clinical development. The authors declare no further competing financial interests.